News

Filter

Current filters:

FabrazymePharmaceutical

1 to 9 of 12 results

Genzyme Framingham plant now cleared by US and EU regulators

24-01-2012

French drug major Sanofi (Euronext: SAN) said yesterday that the US Food and Drug Administration has…

BiotechnologyFabrazymeGenzymePharmaceuticalRare diseasesRegulationSanofi

Ongoing supply problems for Genzyme’s Cerezyme

19-09-2011

US biotech Genzyme, now a subsidiary of French drug major Sanofi (Euronext: SAN), says it will have only…

BiotechnologyCerezymeFabrazymeGenzymeMarkets & MarketingPharmaceuticalRare diseasesSanofiShire

Shire says Fabry and Gaucher disease studies continue to support patient switches to Replagal and Vpriv

01-09-2011

Ireland-headquartered specialty drug firm Shire (LSE: SHP) reported positive data from several studies…

CerezymeFabrazymeGenzymePharmaceuticalRare diseasesReplagalResearchSanofiShireVpriv

Genzyme’s 2nd-qtr 2010 profits plunge on continuing Cerezyme and Fabrazyme supply problems

22-07-2010

Troubled US biotechnology firm Genzyme yesterday revealed that net profit for the second quarter of 2010…

BiotechnologyCerezymeFabrazymeFinancialGenzymePharmaceutical

Genzyme signs consent decree with US FDA to correct violations at manufacturing plant and give up $175 million in profits

25-05-2010

Troubled US biotechnology firm Genzyme has signed a consent decree agreeing to correct manufacturing…

BiotechnologyCerezymeFabrazymeFinancialGenzymeNorth AmericaPharmaceuticalRare diseasesRegulationThyrogen

US FDA to take enforcement action regarding Genzyme’s Allston plant, including financial penalties

25-03-2010

In another setback for the troubled biotechnology firm, the US Food and Drug Administration has notified…

BiotechnologyCerezymeFabrazymeFinancialGenzymeMyozymeNorth AmericaPharmaceuticalRare diseasesRegulationThyrogen

1 to 9 of 12 results

Back to top